TrialBreast cancer research : BCR2025

Genomic alterations are associated with response to aromatase inhibitor therapy for ER-positive postmenopausal ductal carcinoma in situ: (CALGB 40903, Alliance).

Jeffrey R Marks et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.